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Management of patients with KPC-harboring Enterobacteriaceae has become a signiﬁcant and challenging scenario. We report
three cases of KPC-producing Klebsiella pneumoniae bacteremia that were successfully treated using combination therapy with
polymyxin B and other antimicrobials. Serum bactericidal titers were determined and provided additional clinical guidance in the
management of such patients.
1.Introduction
Traditionally in vitro susceptibility testing utilizing the mini-
mal inhibitory concentration (MIC) has been used to guide
antimicrobial treatment[1].However,using thisasatoolhas
led to problems because of failure to detect complex resistan-
ce mechanisms using established guidelines. For more diﬃ-
cult-to-treat infections, such as endocarditis, serum bacteri-
cidal titers (SBT) have been used to guide therapeutic man-
agement and determine antibiotic interactions during ther-
apy [1, 2]. SBT are determined by obtaining serum samples
frompatients before (trough)and/or after(peak)the admin-
istrationoftheantimicrobialtherapy.Afterserialdilutionsof
the serum sample, the sample is incubated with the infecting
organism to determine the highest dilution with bactericidal
activity [1]. Indirectly, this test will assess the antimicrobial
susceptibility of the organism (pharmacodynamics) as well
as the free antimicrobial serum concentration (pharmacoki-
netic).
With increasing prevalence of carbapenemase producing
Enterobacteriaceae, the antimicrobial management has been
challenging, as these organisms also harbor resistance to
multiple antimicrobials [3]. Thus, based on clinical labora-
tory sensitivities, use of fosfomycin, polymyxins, and tige-
cycline alone or in combination, may be the only antimicro-
bials left with activity against these organisms [3, 4]. As a re-
sult, some have used antimicrobial combination therapy for
the theoretical synergistic advantages, in an eﬀort to improve
outcomes [5]. Antimicrobial combination therapy against
carbapenemase-producing organisms have been evaluated
usingtimetokillassaysorcheckerboard;however,nostudies
have been done using SBT to monitor outcomes. Here we re-
port three cases of patients with serious infections with
Klebsiella pneumoniae (KP) possessing KPC carbapenemases
treated with combination therapy and SBT evaluation.
2.Case1
An 87-year-old man, nursing-home resident, with a history
of dementia, benign prostatic hyperplasia, and chronic
obstructive pulmonary disease was transferred to the East2 Case Reports in Medicine
Orange Veteran’s Aﬀairs (EOVA) Hospital for fever, chills,
lethargy, and hypotension. On evaluation at EOVA, he ap-
pearedconfusedanddisoriented,complainingofgeneralized
weakness and urinary hesitancy. His temperature was 99.1◦F
orally;bloodpressurewas92/57mmHg,withheartrateof90
beats per minute and respiratory rate of 21breath per min-
ute. Physical examination revealed bilateral crackles at the
lung bases. Laboratory results showed a white blood cell
(WBC) count of 14.3 × 109/L with 78.8% neutrophils. a
Foley catheter was placed and a urinalysis showed 50–70
WBCs, 30–50 red blood cells per high power ﬁeld (HPF),
and many bacteria. Initial chest radiograph (CXR) revealed a
newsmallrightmedialbasilaropacitythatwassuspiciousfor
subsegmental atelectasis. Levoﬂoxacin was started for sus-
pected health-care associated pneumonia and after intraven-
ous hydration a repeat CXR did not show any evidence of
aninfectiousprocess.Despiteantibiotictherapy,patientcon-
tinued to have fever of 101.4◦F and one out of two sets
of blood cultures and urine culture grew multidrug-resis-
tant Klebsiella pneumoniae. Levoﬂoxacin was changed to
doripenem 1 gram IV every eight hours and polymyxin B
500,000 IV units every 12 hours to treat a complicated uri-
narytractinfectionwithsecondarybacteremia.Repeatblood
cultures after two days on the new antibiotic regimen were
negative and his fever and leukocytosis resolved. He com-
pleted a 14-day course of doripenem and polymyxin B with-
out any reported adverse event and was transferred back to
the extended care facility in a stable condition.
3.Case2
A60-year-oldmanwithpastmedicalhistoryofseizuredisor-
der, ischemic cerebrovascular event, atrial ﬁbrillation, hyper-
tension, coronary artery disease, and diabetes was trans-
ferred from a long-term care facility to the EOVA Hospital
after suﬀering witnessed tonic-clonic seizures. EEG showed
nonconvulsive status epilepticus. He required endotracheal
intubation and intravenous fosphenytoin, propofol and
phenobarbital were started but his EEG continued to show
status epilepticus. His hospital course was complicated by
Clostridium diﬃcile diarrhea and septic shock. He was empi-
rically started on vancomycin, piperacillin/tazobactam, and
metronidazole. A CXR showed a right lower inﬁltrate and
along with purulent sputum he was diagnosed with a venti-
lator associated pneumonia. His sputum and blood culture
grew multidrug-resistant Klebsiella pneumoniae and his anti-
biotic regimen was changed to tigecycline 50mg IV every
12 hours and polymyxin B 600,000 IV units every 12 hours.
With the new antimicrobial regimen his fever resolved and
his repeat blood cultures remained negative. His liver and
kidney function tests were stable during his 10-day course of
antimicrobials.Duetothelackofimprovementofhismental
status a brain CT was done and revealed acute ischemic
changes in the territories of the left middle cerebral artery
andleftposteriorcerebralartery.Thepalliativecareteamdis-
cussed the patient’s poor prognosis with his family and the
decisionwasmadetowithdrawallacutemedicalcare.Hewas
terminally extubated, placed on comfort care protocol, and
died within 24 hours.
4.Case3
A 66-year-old man with past medical history of atrial ﬁbril-
lation and hypertension presented to the emergency room of
the EOVA with a two-day history of shortness of breath. He
was recently hospitalized for right-sided hemicolectomy due
toatubularadenomainthececum.Onphysicalexamination
he had a temperature of 99.4◦F, heart rate of 100 beats per
minute, respiratory rate of 20 breath per minute, and oxygen
saturation on 97% on 2 liters nasal cannula. Breath sounds
weredecreasedontherightlowerlungﬁeldandhisabdomen
revealed a well-healed surgical scar without any surrounding
erythema. Laboratory workup showed a WCB of 12.3 ×
109/L, with 83% neutrophils. A portable CXR showed a
large right-sided pleural eﬀusion that was drained through a
chest tube. Pleural ﬂuid analysis was consistent with a trans-
udate and pleural ﬂuid cultures were negative. Three days
later, the patient had a temperature of 101.8◦Fw i t hc o m -
plains of dysuria, his white blood cell count increased to
14.4 × 109/L and urine analysis showed 30–49 WBC/HPF.
Of note, a Foley catheter had been placed on admission but
was removed 48 hours later. Ciproﬂoxacin was empirically
started for urinary tract infection; however, he continued to
have fevers up to 102◦F, was tachycardic, and had persistent
dysuria. Urine culture and blood cultures grew multidrug-
resistant Klebsiella pneumoniae. Ciproﬂoxacin was changed
to doripenem 1 gram IV every 12 hours, (infused over 3
hours), rifampin 300mg orally every 12 hours and polymy-
xin B 250,000 units IV every 12 hours adjusted for a creati-
nine clearance of 42mL/min. Soon after this antibiotic com-
bination was started, the fever and leukocytosis resolved and
repeat blood and urine cultures were negative. Kidney and
liver function tests were stable during the 14-day course of
antimicrobials.
5. Methods
Blood culture isolates of KP were collected from the clini-
cal microbiology laboratory and tested for SBT. All KP
blood isolates were resistant to amikacin, gentamicin, cipro-
ﬂoxacin, levoﬂoxacin, imipenem, meropenem, ertapenem,
cefe-pime, piperacillin-tazobactam, trimethoprim-sulfa-
meth-oxazole, and ceftriaxone and susceptible to tigecycline
and polymyxin B by E-test (AB bioMeri´ eux, Marcy l’Etoile,
France). All isolates were blaKPC positive by PCR. Serum
samples for SBT were collected after 24 hours of antimic-
robial treatment. Serum collected 30 minutes after the last
antibiotic infusion and 30 minutes before the next antibiotic
administration were used for the peak and trough SBT, res-
pectively. Serum samples were frozen at −80◦C and SBT test-
ing was performed at New York Hospital Queens (NYHQ)
in the Infectious Diseases Research Laboratory. SBT was
performed according to the standardized microdilution
method using cation-adjusted Mueller-Hinton broth as dil-
uent and 105 colony-forming units/mL as inoculums [6].
The test is performed by serially diluting (twofold) the pa-
tientserumandinoculatingitwithaknownconcentrationof
the infecting organism isolated from the same patient. After
a20-hourincubation,theinhibitorytiter(SIT)isdeterminedCase Reports in Medicine 3
Table 1: Peak and trough serum inhibitory/bactericidal titers.
Peak Trough MIC (µg/mL) by Etest
Isolate SIT SBT SIT SBT DOR PO TG RIF
Case 1
P atient 1:32 1:32 1:16 1:16 >32 0.5
NYHQ KP 1:4 1:4 1:4 1:4 3 6
E. coli >1:1024 >1:1024 >1:1024 >1:1024 0.016 0.5 0.125 12
KP SHV-18 1:256 1:256 1:128 1:128 0.064 1 ND >32
Case 2 Patient 1:32 1:32 1:32 1:16 16 2 3-4
Case 3 P atient 1:8 1:8 1:8 1:8 3 3 >32
NYHQ KP 1:8 1:8 1:8 1:8 >32 32 >32
SIT: serum inhibitory titers; SBT: serum bactericidal titers; MIC: minimal inhibitory concentration; DOR: doripenem; PO: polymyxin B; TG: tigecycline; RIF:
rifampin; KP: Klebsiella pneumoniae; ND: not done.
by visually examining the well with the highest dilution
showing no growth of the organism. A speciﬁed volume is
then subcultured from each tube that shows no growth. The
plates are then incubated overnight and the resulting colon-
ies are counted. The serum bactericidal titer is the highest
dilution for which a deﬁned percentage (99.9%) of killing of
the original inoculum can be demonstrated. The turnaround
t i m ef o rt h i st e s ti sa p p r o x i m a t e l y4 8h o u r s .Escherichia coli
ATCC25922,twowell-characterizedKPisolatesfromNYHQ
with decreased polymyxin B susceptibility, and a KP ATCC
700603 (SHV-18 positive) were also used to assess the bac-
tericidal and inhibitory activity of the polymyxin B combi-
nation therapy. All SBT tests were done in duplicate for con-
sistency.
6. Results
Although an absolute SBT has not been clearly established,
most studies have found that SBT of at least 1:4 and 1:8 are
neededtoensureasuccessfuloutcome[1].Serumcontaining
combination therapy with polymyxin B and doripenem was
bactericidal against the patient isolate in case 1 with a peak
SBT of 1:32 (Table 1) .H o w e v e r ,a g a i n s ta nN Y Q HK Pc o n -
trol isolate with decreased polymyxin susceptibility, the peak
SBT was only 1:4. Although the NYQH KP control isolate
showed a lower peak SBT than the patient isolate, there was
bactericidal activity throughout the dosing interval (trough
SBT of 1:4) despite the resistance to polymyxin and dori-
penem. The higher peak/trough SBT seen against the KP
SHV-18 isolate (doripenem and polymyxin susceptible)
could be explained by the combined activity of doripenem
andpolymyxin.Incase2,serumcontainingpolymyxinBand
tigecycline combination therapy was bactericidal with a peak
SBT 1:32. Combination therapy with this serum was not
tested against isolates with decreased polymyxin B suscep-
tibility due to insuﬃcient patient serum. In case 3, combina-
tion therapy was bactericidal with a peak SBT of 1:8 for
both, the patient isolate and an NYQH KP isolate with de-
creased polymyxin susceptibility. The patient isolate in case 3
had decreased susceptibility to polymyxin B and doripenem
with an MIC of 3µg/mL and >32µg/mL, respectively. In all
patients, the trough levels were ≥1:4 which indicates that
bactericidal activity was maintained throughout the dosing
regimen.
7. Discussion
KPC-producing KP has been consistently resistant to multi-
ple antimicrobials, being generally susceptible to polymyx-
ins, tigecycline, fosfomycin, and variable susceptibility to
aminoglycosides [3]. As a result, polymyxins now have an in-
creasing role in the treatment of these infections. Even
though limited clinical studies have failed to demonstrate
that polymyxin combination therapy is more eﬀective than
polymyxin monotherapy, many clinicians have combined
polymyxins with other agents for synergy and concerns of
resistance development during therapy [7–9]. In a literature
review of patients (n = 18) treated with polymyxins, com-
bination therapy had a higher success rate than the mono-
therapy (73% versus 14%) [3]. The authors suggest that the
higher failure rate of polymyxin monotherapy could be due
to the development of resistance during therapy. A study by
Thiolas et al. suggests the use of colistin with imipenem to
circumvent the successive emergence of resistance on mono-
therapy with each agent [10]. Lee et al. reported decreased
polymyxin B susceptibility in 20% of patients with KPC-
positive KP infections treated with polymyxin B monother-
apy(n = 12)butcombinationtherapywithpolymyxinBand
tigecycline prevented the emergence of resistance to either
antibiotic [11].
With escalating resistance, clinicians are utilizing more
antimicrobial combination regimens for treatment of KPC-
producing KP infections [5]. In a study of antibiotic combi-
nation therapy for KPC-producing Enterobacteriaceae,p o l y -
myxins were found to have bactericidal activity only in the
ﬁrst eight hours of treatment, with regrowth thereafter using
time-kill curve analysis [12]. However, combination therapy
with tigecycline and colistin was found to have bactericidal
and synergistic activity at 24 hours. We have encountered
similar results with diﬀerent polymyxin B combination
therapy, in which bactericidal activity was noted throughout
the dosing intervals based on consistent trough bactericidal
titers found in our patients.
In a recent study by Urban et al. combination therapy of
polymyxin B, doripenem, and rifampin showed bactericidal4 Case Reports in Medicine
activityusing time-kill curveagainsttwostrainsof KPC-pro-
ducing KP [13]. Combination of any two of the three anti-
biotics tested, showed no bactericidal activity against the iso-
lates.Furthermore,combinationtherapyseemstohavearole
in isolates with decreased polymyxins susceptibility [14]. In
this study, the serum of all three patients contained poly-
mixin B and an additional antibiotic, so we cannot assume
that the bactericidal activity seen in the combination therapy
was not solely due to polymyxin B. However, the bactericidal
activity noted against polymyxin-resistant KP isolates in our
study indicates that there might be some synergism. SBT re-
sults from study case number 3 showed that the combination
of polymyxin B, rifampin, and doripenem had bactericidal
activity despite showing resistance against each individual
agent.
Tigecycline has been used in the treatment of carbape-
nem-resistant organisms; however, its low serum levels are
a concern in bacteremic patients [15], thus combination
therapy may be beneﬁcial in treatment of KPC KP bactere-
mia. Humphries et al. were able to treat colistin-resistant
KPC-positive KP bacteremia with tigecycline and colistin
[15]. We also obtained microbiological cure with a combina-
tion of tigecycline and polymyxin B, and we believe that tige-
cycline can be an important addition in the treatment of
KPC-producingKPbacteremiaifusedincombinationthera-
py. Doripenem is the newest carbapenem available in the
market, and was used in combination therapy in two of our
patients. In a recent animal study, doripenem given as 4-
hour infusion was noted to produce modest CFU reduction
(1 log reduction) of KPC-producing KP in the presence of
white blood cells, irrespective of the doripenem MIC (range
from 4 to 32µg/dL) [16]. The results did not showed any
bactericidal activity but the authors concluded that in im-
munocompetent patients, doripenem might have a role, in
combinationtherapy,inthetreatmentofKPC-producingKP
infections.
Most studies of combination therapy for KPC-producing
KP infections had been done in vitro with the use of time-
kill curves or checkerboards which do not take into account
the pharmacokinetics of the antibiotics used. Polymyxins
have been in clinical use for over four decades but variable
pharmacokinetics of this class of antibiotics has been report-
ed [17]. SBT has the theoretical advantage of assessing the
pharmacokinetic and pharmacodynamics of the antimicro-
bials in an individual patient [18, 19]. In a case report of
a vancomycin-resistant Enterococcus faecium endocarditis
treated with daptomycin, clinical failure was predicted by the
SBT and not the MIC [20]. Low free daptomycin levels were
found due to its high protein aﬃnity which was not assessed
by the MIC.
SBT has been used to evaluate antibiotic interactions in
combination therapy [21–23] and to predict clinical out-
come. Martino et al. reported that peak and trough SBT of
>1:8 of beta-lactam-aminoglycosides combination therapy
predictedclinicalsuccessinneutropenicpatientswithGram-
negativesepticemia[24].SimilarpeakSBTof>1:8predicted
clinical success in endocarditis [25] and in oncology patients
with septicemia and wound infections [18]. Patients who re-
ceive combination therapy have higher SBT and higher cure
rate than patients who received only single-agent therapy,
suggesting the possibility of synergism [18]. However, if SBT
of ≥1:16 are obtained, this correlates with good clinical out-
come despite the use of single or combination antimicrobial
therapy [24]. SBT has also been used in the management of
osteomyelitis [26], acute pulmonary exacerbation in cystic
ﬁbrosis patients [27], and treatment of infections caused by
organisms withreducedantimicrobial susceptibility [28,29].
Variability of the SBT among diﬀerent laboratories was a
limiting factor for the acceptance of this test for clinical use
[30, 31]. Timing of the sampling of the specimens relative to
the antibiotic dose, variation of the dilution of serum, size of
bacterial inoculum, culture media used, and time of incuba-
tion were among the factors accounting for intra- and inter-
laboratory variability. However, standardized methods for
the SBT determination have been published and endorsed by
national guidelines [6].
Microbiological success was obtained in our three cases
ofKPCproducingKPbacteremiawithdiﬀerentpolymyxin B
containing combination therapies. Clinical success was seen
in two of the patients with the third patient expiring from
other medical comorbidities. As the MIC for polymixin B
increases,theSBTdecreasesforthethreeantibioticcombina-
tionsusedhighlightingtheimportanceofpolymixinBforin-
creased bactericidal activity with combination therapy for
the treatment of KPC-producing KP infections. Therefore,
according to the results of our study, combination therapy
with polymixin B-containing therapies may be an option in
the treatment of bacteremia caused by KPC-producing KP.
Additionally, SBT may have a role in the guidance of treat-
ment of patients with carbapenem-resistant KP infections
and other multidrug-resistant Gram-negative bacteria.
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